Respiratory Medicine
Volume 104, Issue 10 , Pages 1391-1395, October 2010

Involvement of type II pneumocytes in the pathogenesis of chronic obstructive pulmonary disease

  • Chun-zhen Zhao

      Affiliations

    • Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China
  • ,
  • Xiao-cong Fang

      Affiliations

    • Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China
    • Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, China
  • ,
  • Diane Wang

      Affiliations

    • Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China
  • ,
  • Fa-di Tang

      Affiliations

    • Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 46 46 125 931.
  • ,
  • Xiang-dong Wang

      Affiliations

    • Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China
    • Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, China
    • Corresponding Author InformationCorresponding author. Zhejiang Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, College of Medical Sciences, Zhejiang University, China

Received 31 January 2010; accepted 25 June 2010. published online 21 July 2010.

Summary 

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, but the cellular and molecular mechanisms are still not fully understood. Type II pneumocytes are identified as the synthesizing cells of the alveolar surfactant, which has important properties in maintaining alveolar and airway stability. Lung surfactant can reduce the surface tension and prevent alveolar collapse and the airway walls collapse. Pulmonary surfactant components play important roles in normal lung function and inflammation in the lung. Surfactant has furthermore been shown to modulate the process of innate host defense, including suppression of cytokine secretion and transcription factor activation, in the inflammatory network of COPD. Abnormalities of lung surfactant might be one of the mechanisms leading to increased airway resistance in COPD. The increased expression of Granzyme A and B was found in lung tissues of patients with COPD and type II pneumocytes was proposed to be involved in the pathogenesis of COPD. These novel findings provide new sights into the role of the type II pneumocytes in the pathogenesis of COPD.

Keywords: Type II pneumocytes, Chronic obstructive pulmonary disease, Surfactant, Patients, Lung

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0954-6111(10)00297-0

doi:10.1016/j.rmed.2010.06.018

Respiratory Medicine
Volume 104, Issue 10 , Pages 1391-1395, October 2010